An expert panel of pain management physicians determined that ziconotide, a non-opioid and non-NSAID analgesic, should be the first-line spinal treatment of nociceptive and neuropathic chronic pain at the 2011 Polyanalgesic Consensus Conference, according to a news release.
The panel, which consisted of 29 clinicians and the faculty of the North American Neuromodulation Society, also recommended ziconotide as the preferred option for spinal administration compared to opioids when there is a concern for recurrent granuloma, a type of inflammation that occurs when immune cells collect. The expert panel recommendation was based on an extensive literature search and a survey of more than 15,000 clinicians worldwide.
Related Articles on Pain Management:
ASC Specialty to Watch: Pain Management in 2012
15 Statistics on Pain Management Case Revenue
Tennessee Requires Pain Management Clinics to Register with State
The panel, which consisted of 29 clinicians and the faculty of the North American Neuromodulation Society, also recommended ziconotide as the preferred option for spinal administration compared to opioids when there is a concern for recurrent granuloma, a type of inflammation that occurs when immune cells collect. The expert panel recommendation was based on an extensive literature search and a survey of more than 15,000 clinicians worldwide.
Related Articles on Pain Management:
ASC Specialty to Watch: Pain Management in 2012
15 Statistics on Pain Management Case Revenue
Tennessee Requires Pain Management Clinics to Register with State